<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4567">
  <stage>Registered</stage>
  <submitdate>5/08/2014</submitdate>
  <approvaldate>5/08/2014</approvaldate>
  <nctid>NCT02210169</nctid>
  <trial_identification>
    <studytitle>RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates</studytitle>
    <scientifictitle>A Randomised Controlled Trial (RCT) of Continuous and Intermittent Infusion of Vancomycin in Neonates</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Vanc_IIV vs CIV</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis</healthcondition>
    <healthcondition>Infection</healthcondition>
    <healthcondition>Bacteremia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Continuous infusion of vancomycin

No Intervention: Intermittent infusion of vancomycin - Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.

Active Comparator: Continuous infusion of vancomycin - A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.


Treatment: drugs: Continuous infusion of vancomycin
Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of neonates achieving target vancomycin concentrations in blood at steady state (48 hours)</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Neonates in the neonatal unit with an infection requiring treatment with vancomycin as
        determined by the treating physician.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Infants born at a gestational age &lt; 25 weeks.

          -  Allergy to vancomycin or other glycopeptide antibiotic

          -  Vancomycin administered within the previous 72 hours

          -  Renal impairment

          -  Prior enrolment in the study

          -  Need for drug that is incompatible with vancomycin (if not other IV line is available)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Children's Hospital - Melbourne</hospital>
    <hospital>Mercy Hospital for Women - Melbourne</hospital>
    <postcode>3052 - Melbourne</postcode>
    <postcode>3084 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Childrens Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Children's Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Mercy Hospital for Women, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will
      be recruited. They will be randomised to receive vancomycin as an intermittent infusion (over
      1 hour) or as a continuous infusion (over 24 hours). The hypothesis is that administering
      vancomycin as a continuous infusion will result in improved attainment of target
      concentrations in blood at steady state (when the drug is in equilibrium) compared to
      intermittent infusion.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02210169</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amanda Gwee, MBBS</name>
      <address>Murdoch Children's Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Gwee, MBBS</name>
      <address />
      <phone>9345 5522</phone>
      <fax />
      <email>amanda.gwee@rch.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>